25 Mar, 2019

CIRCULOGENE’s Precision Genomic Profiling Technology Featured in Three AACR 2019 Abstracts

Posters present data on utility of cfDNA for patient mutation load in NSCLC; cfRNA PD-L1 + MSI single-blood-tube testing; and innovative salvage of buccal NGS testing BIRMINGHAM, Ala.--(BUSINESS WIRE)-- CIRCULOGENE, advancing precision medicine through personalized [...]

19 Feb, 2019

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director. Dr. Schmidt will lead the [...]

13 Feb, 2019

CIRCULOGENE Molecular Diagnostics Laboratory Receives College of American Pathologists (CAP) Accreditation

 BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through personalized molecular genetics testing, announced today that its molecular diagnostics laboratory has received College of American Pathologists (CAP) accreditation based on a recent on-site inspection as part [...]

3 Jan, 2019

CIRCULOGENE Expands Molecular Diagnostics Testing Footprint To Asia-Pacific Region

DATE: January 3, 2019 CIRCULOGENE Expands Molecular Diagnostics Testing Footprint To Asia-Pacific Region Strategic partnership broadens cancer-targeted molecular diagnostics and immunotherapy testing to rapidly growing Asia-Pacific market. BIRMINGHAM, Ala.– CIRCULOGENE, advancing precision medicine through molecular genetics [...]

20 Dec, 2018

CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019

FOR IMMEDIATE RELEASE DATE: December 20, 2018 CIRCULOGENE to Launch Comprehensive, 20-Fusion NTRK Biomarker Testing in Early 2019 Proprietary, cfRNA-enriched, real-time PCR testing rapidly identifies all patients with NTRK fusion-positive cancers potentially eligible for new TRK [...]

19 Sep, 2018

CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing

CIRCULOGENE Expands Testing Menu with Somatic BRCA1/2 Blood Testing Enables paired somatic-germline testing, broadens targeted treatment population for breast, ovarian, pancreatic and prostate cancers   BIRMINGHAM, Ala. – CIRCULOGENE, advancing precision medicine through molecular genetics testing, has [...]

19 Jun, 2018

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer Patients Independent UAB study demonstrates potential value of company’s molecular testing in noninvasive, serial tracking of genomic changes in treatment-resistant ovarian cancer BIRMINGHAM, Ala.– [...]

29 May, 2018

REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM

REQUEST FOR APPLICATIONS CIRCULOGENE – RESEARCH SAMPLE PROFILING PILOT AWARD PROGRAM Applications due: 5pm EST on August 1, 2018 Award announcements: anticipated by September 15, 2018 Pilot Award Details: Made possible by CIRCULOGENE, this pilot [...]

3 Jan, 2018

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory

CIRCULOGENE Announces International Licensing of Proprietary Molecular Diagnostics Testing Technology to Turkey-Based Laboratory Company expands single-blood-tube, cancer-targeted therapy and immunotherapy testing to parts of Europe, Africa, the Middle East and Commonwealth of Independent States (CIS) [...]

20 May, 2016

Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference

Circulogene Announces Four Abstracts Accepted for ASCO 2016 Conference Research involving Circulogene’s single-drop-volume liquid biopsy assays for real-time monitoring of cancer mutations included in ASCO 2016 BIRMINGHAM, Ala., May 20, 2016 (BUSINESS WIRE) – Circulogene Theranostics, the only biotechnology [...]